Proteomic investigation of taxol and taxotere resistance and invasiveness in a squamous lung carcinoma cell line

Biochimica et Biophysica Acta - Proteins and Proteomics

Volumn 1784, Issue 9, 2008, Pages 1184-1191

  Murphy, L ^a   Henry, M ^a   Meleady, P ^a   Clynes, M ^a   Keenan, J ^a  

^a DUBLIN CITY UNIVERSITY   (Ireland)

Author keywords

Drug resistance; Lung cancer; Proteomics; Taxol; Taxotere

Indexed keywords

BETA TUBULIN; CYTOSKELETON PROTEIN; DOCETAXEL; DOXORUBICIN; ETOPOSIDE; FLUOROURACIL; GLYCOPROTEIN P; PACLITAXEL; VINCRISTINE; ANTINEOPLASTIC AGENT; REACTIVE OXYGEN METABOLITE; TAXOID; TUMOR PROTEIN;

ARTICLE; CANCER CELL CULTURE; CONTROLLED STUDY; DRUG MECHANISM; HUMAN; HUMAN CELL; IN VITRO STUDY; LUNG CARCINOMA; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN METABOLISM; PROTEOMICS; TWO DIMENSIONAL ELECTROPHORESIS; CANCER INVASION; CELL ADHESION; DRUG RESISTANCE; GENETICS; LUNG TUMOR; METABOLISM; PATHOPHYSIOLOGY; PHYSIOLOGY; SQUAMOUS CELL CARCINOMA; TUMOR CELL LINE; TWO DIMENSIONAL GEL ELECTROPHORESIS;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; CARCINOMA, SQUAMOUS CELL; CELL ADHESION; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; ELECTROPHORESIS, GEL, TWO-DIMENSIONAL; HUMANS; LUNG NEOPLASMS; NEOPLASM INVASIVENESS; NEOPLASM PROTEINS; P-GLYCOPROTEIN; PACLITAXEL; PROTEOMICS; REACTIVE OXYGEN SPECIES; TAXOIDS;

EID: 53149138610     PISSN: 15709639     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbapap.2008.04.014     Document Type: Article

References (40)

1. A. Jemal, T. Murray, E. Ward, A. Samuels, R.C. Tiwari, A. Ghafoor, E.J. Feuer, M.J. Thun, Cancer Statistics, 2005, CA Cancer J. Clin. 55 (2005) 10-30.
2. H. Parekh, K. Wiesen, H. Simpkins, Acquisition of taxol resistance via pglycoprotein and non-p-glycoprotein-mediated mechanisms in human ovarian carcinoma cells, Biochem. Pharmacol. 53 (1997) 461-470.
3. W.B. Pratt, R.W. Ruddon, W.D. Ensminger, J. Maybaum, The Anticancer drug, Second Edition. Oxford University Press, New York, 1994.
4. T.H. Wang, H.S. Wang, Y.K. Soong, Paxlitaxel-induced cell death where the cell cycle and apoptosis come together, Cancer 88 (2000) 2619-2628.
5. M. Schibler, F. Cabral, Taxol-dependent mutants of Chinese hamster ovary cells with alterations in a- and β-tubulin, J. Cell Biol. 102 (1986) 1522-1531.
6. K.A. Hotchkiss, A.W. Ashton, R. Mahmood, R.G. Russell, J.A. Sparano, L. Edward, E.L. Schwartz, Inhibition of endothelial cell function in vitro and angiogenesis in vivo by docetaxel (taxotere): association with impaired repositioning of the microtubule organizing centre, Mol. Cancer Therapeutics 1 (2002) 1191-1200.
7. S.M. Simon, M. Schindler, Cell biological mechanisms of multidrug resistance in tumours, Proc. Natl. Acad. Sci. U. S. A. 91 (1994) 3497-3504.
8. P.G. Righetti, A. Castagna, P. Antonioli, D. Cecconi, N. Campostrini, S.C. Righetti, Proteomic approaches for studying chemoresistance in cancer, Expert Rev. Proteomics 2 (2005) 215-228.
9. E. Laemmli, M. Favre, Mutation of the head of bacteriophage T4, J. Mol. Biol. 80 (1973) 575-579.
10. H. Towbin, T. Staehelin, J. Gordon, Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedures and some applications, Proc. Natl. Acad. Sci. U. S. A. 76 (1979) 4350-4354.
11. A. Albini, A. Melchiori, L. Santi, L.A. Liotta, P.D. Brown, W.G. Stetler-Stevenson, Tumor cell invasion inhibited by TIMP-2, J. Natl. Cancer Inst. 83 (1991) 775-779.
12. U. Vaishampayan, R.E. Parchment, B.R. Jasti, M. Hussain, Taxanes: an overview of the pharmacokinetics and pharmacodynamics, Urology, 54 (Suppl 6A) (1999) 22-29.
13. S. Noguchi, Predictive factors for response to docetaxel in human breast cancers, Cancer Sci. 97 (2006) 813-820.
14. F. Vandermoere, I. El Yazidi-Belkoura, C. Slomianny, Y. Demont, G. Bidaux, E. Adriaenssens, J. Lemoine, H. Hondermarck, The valosin-containing protein (VCP) is a target of Akt signaling required for cell survival, J. Biol. Chem. 281 (2006) 14307-14313.
15. T. Namba, T. Hoshino, K. Tanaka, S. Tsutsumi, T. Ishihara, S. Mima, K. Suzuki, S. Ogawa, T. Mizushima, Up-regulation of 150-kDa oxygen-regulated protein by celecoxib in human gastric carcinoma cells, Mol. Pharmacol. 71 (2007) 860-870.
16. D.R. Ciocca, S.K. Calderwood, Heat shock proteins in cancer: diagnostic, prognostic, predictive, and treatment implications, Cell Stress Chaperones 10 (2005) 86-103.
17. H.W. Tsai, N.H. Chow, C.P. Lin, S.H. Chan, C.Y. Chou, C.L. Ho, The significance of prohibitin and c-Met/hepatocyte growth factor receptor in the progression of cervical adenocarcinoma, Human Pathol. 37 (2006) 198-204.
18. A. Johnsson, I. Seelenberg, Y. Min, J. Hilinski, C. Berry, S. Howell, G. Brit, Identification of genes differentially expressed in association with acquired cisplatin resistance, Brit. J. Cancer 83 (2000) 1047-1054.
19. S. Rastogi, B. Joshi, P. Dasgupta, M. Morris, K. Wright, S. Chellappan, Prohibitin facilitates cellular senescence by recruiting specific corepressors to inhibit E2F target genes, Mol. Cell. Biol. 26 (2006) 4161-4171.
20. P. Alfonso, M. Catalá, M.L. Rico-Morales, D. Durante- Rodríguez, E. Moro-Rodríguez, H. Fernández-García, J.M. Escribano, E. Alvarez-Fernández, E. García-Poblete, Proteomic analysis of lung biopsies: differential protein expression profile between peritumoral and tumoral tissue, Proteomics 4 (2004) 442-447.
21. L. Emert-Sedlak, S. Shangary, A. Rabinovitz, M.B. Miranda, S.M. Delach, D.E. Johnson, Involvement of cathepsin D in chemotherapy-induced cytochrome c release, caspase activation, and cell death, Mol. Cancer Ther. 4 (2005) 733-742.
22. H. Inoue, A. Kawada, H. Takasu, R. Maruyama, Y. Hata, M. Hiruma, S. Tajima, A. Ishibashi, Cathepsin D expression in skin metastasis of breast cancer, J. Cutan. Pathol. 25 (1998) 365-369.
23. G. Varbiro, B. Veres, F. Gallyas, B. Sumegi, Direct effect of taxol on free radical formation and mitochondrial permeability transition, Free Radic. Biol. Med. 31 (2001) 548-558.
24. Q. Kong, J.A. Beel, K.O. Lillehei, A threshold concept for cancer therapy, Med. Hypotheses 55 (2000) 29-35.
25. B. Ramanathan, K.Y. Jan, C.H. Chen, T.C. Hour, H.J. Yu, Y.S. Pu, Resistance to paclitaxel is proportional to cellular total antioxidant capacity, Cancer Res. 65 (2005) 8455-8460.
26. J. Martinez-Heredia, J.M. Estanyol, J.L. Ballesca, R. Oliva, Proteomic identification of human sperm proteins, Proteomics 6 (2006) 4356-4369.
27. S. Tanaka, T. Uehara, Y. Nomura, Up-regulation of protein-disulfide isomerase in response to hypoxia/brain ischemia and its protective effect against apoptotic cell death, J. Biol. Chem. 275 (2000) 10388-10393.
28. D.Y. Noh, S.J. Ahn, R.A. Lee, S.W. Kim, I.A. Park, H.Z. Chae, Overexpression of peroxiredoxin in human breast cancer, Anticancer Res. 21 (2001) 2085-2090.
29. M.M. Christian, R. Moy, R.F. Wagner, A. Moore, A correlation of alpha smooth muscle actin and invasion in micronodular basal cell carcinoma, Dermatol. Surg. 27 (2001) 1524-1547.
30. N.M. Verrills, N.L. Liem, T.Y. Liaw, B.D. Hood, R.B. Lock, M. Kavallaris, Proteomic analysis reveals a novel role for the actin cytoskeleton in vincristine resistant childhood leukemia-an in vivo study, Proteomics 6 (2006) 1681-1694.
31. A. Taguchi, D.C. Blood, G. del Toro, A. Canet, A.D.C. Lee, W. Qu, N. Tanji, Y. Lu, E. Lalla, C. Fu, M.A. Hofmann, T. Kislinger, M. Ingram, A. Lu, H. Tanaka, O. Hori, S. Ogawa, D.M. Stern, A.M. Schmidt, Blockade of RAGE-amphoterin signalling suppresses tumour growth and metastasis, Nature 405 (2000) 354-360.
32. H.J. Spence, L. McGarry, C.S. Chew, N.O. Carragher, S.A. Carragher, Y. Zhengquiang, D.R. Croft, M.F. Olson, M. Frame, B.W. Ozanne, AP-1 differentially expressed proteins Krp1 and fibronectin co-operatively enhance Rho-ROCK-independent mesenchymal invasion by altering the function, localisation, and activity of nondifferentially expressed proteins, Mol. Cell. Biol. 26 (2006) 1480-1495.
33. Y.H. Lin, Z.Y. Park, D. Lin, A.A. Brahmbhatt, M.C. Rio, J.R. Yates III, R.L. Klemke, Regulation of cell migration and survival by focal adhesion targeting of Lasp-1, J. Cell Biol. 165 (2004) 421-432.
34. K. Hibi, W.H. Westra, M. Borges, S. Goodman, D. Sidranski, J. Jen, PGP9.5 as a candidate tumor marker for non-small-cell lung cancer, Am. J. Pathol. 155 (1999) 711-715.
35. F. Brichory, D. Beer, F. Le Naour, T. Giordano, S. Hanash, Proteomics-based identification of protein gene product 9.5 as a tumor antigen that induces a humeral immune response in lung cancer, Cancer Res. 61 (2001) 7908-7912.
36. T. Yamazaki, K. Hibi, T. Takase, E. Tezel, H. Nakayama, K. Kasai, PGP9.5 as a marker for invasive colorectal cancer, Clin. Cancer Res. 8 (2002) 192-195.
37. Y. Hathout, M.L. Gehrmann, A. Chertov, C. Fenselau, Proteomic phonotyping: metastatic and invasive breast cancer, Cancer Lett. 210 (2004) 245-253.
38. J.M. Garcia Pedrero, M.P. Fernandez, R.O. Morgan, A.H. Zapatero, M.V. Gonzalez, C.S. Nieto, J.P. Rodrigo, Annexin A1 down-regulation in head and neck cancer is associated with epithelial differentiation status, Am. J. Pathol. 164 (2004) 73-79.
39. P. Kreunin, C. Yoo, V. Urquidi, D.M. Lubman, S. Goodisons, Proteomic profiling identifies breast tumor metastasis associated factors in an isogenic model, Proteomics 7 (2007) 299-312.
40. D. Jiang, W. Ying, Y. Lu, J. Wan, Y. Zhai, W. Liu, Y. Zhu, Z. Qiu, X. Qian, F. He, Identification ofmetastasis-associated proteins by proteomic analysis and functional exploration of interleukin-18 in metastasis, Proteomics 3 (2003) 724-737.